Clinical Trial

Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)

Study acronym: MONDEGO
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to assess the efficacy, safety and durability of faricimab in caucasian patients with polypoidal choroidal vasculopathy (PCV). The main question it aims to answer is: To evaluate the efficacy of intravitreal (IVT) injections of faricimab 6 milligrams (mg) on Best Corrected Visual Acuity (BCVA) outcomes in caucasian patients with symptomatic macular PCV. Participants will undergo ophthalmic examination, safety assessment and treatment with faricimab according to a patient specific treat and extend regimen.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-11-27; most recent amendment 2026-02-05.
Status change: Not Yet Recruiting → Recruiting 2025-09-30
Trial Details
NCT Number NCT06709339
Lead Sponsor Association for Innovation and Biomedical Research on Light and Image
Conditions Polypoidal Choroidal Vasculopathy
Enrollment 120 participants
Start Date 2025-08-06
Primary Completion 2028-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-06